PAhR Therapeutics

Drug Discovery · Boston, MA · Founded 2025 · Privately Held (backing)

Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms. PAhR Therapeutics is based in Boston, MA and was founded in 2025. It was valued at $25 million at its seed round in Jul 2025, the last priced event on record. It has raised $14 million across 1 recorded round; the latest was a $14 million seed round in Jul 2025.

PMV mark · valuation
$25.0M
Oct 2026
Priced at
its seed round
Jul 2025
Total raised
$14.0M
Last round
Seed Round
Jul 2025
What is PAhR Therapeutics worth?
$25.0MPrivateMarketView mark · Oct 2026

Valued at $25.0M at its seed round, Jul 2025. Nothing has traded since.

Free account
More of PAhR Therapeutics with a free account
  • ·Watch PAhR Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

PAhR Therapeutics funding history

1 rounds
DateRoundRaisedPost-money
Jul 2025Seed Round$14.0M▮
Unlock post-money valuations

Membership and data by Private Market View

PAhR Therapeutics valuation

PAhR Therapeutics was valued at $25 million at its seed round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has PAhR Therapeutics raised?

PAhR Therapeutics has raised $14 million across 1 recorded round since 2025. The largest was a $14 million seed round in Jul 2025.

PAhR Therapeutics has filed 1 Form D with the SEC, most recently in Jul 2025 ($4.7 million sold to 4 investors).

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Persephone Biosciences ($37.3 million), Solarea Bio ($37 million) and Ancilia Bio ($28 million).

How PAhR Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For PAhR Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about PAhR Therapeutics

What is PAhR Therapeutics worth?
PAhR Therapeutics is valued at $25.0M as of Oct 2026. Valued at $25.0M at its seed round, Jul 2025. Nothing has traded since.
How much has PAhR Therapeutics raised?
PAhR Therapeutics has raised $14.0M in total funding across 1 recorded rounds.
When did PAhR Therapeutics last raise?
PAhR Therapeutics last raised in Jul 2025 (Seed Round), raising $14.0M.